Halozyme Therapeutics HALO
$ 45.45
-0.69%
Quarterly report 2024-Q3
added 10-31-2024
Halozyme Therapeutics General and Administrative Expenses 2011-2024 | HALO
Annual General and Administrative Expenses Halozyme Therapeutics
2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
149 M | 144 M | 50.3 M | 45.7 M | 77.3 M | 60.8 M | 53.8 M | 45.9 M | 40 M | 35.9 M | 32.3 M | 24.8 M | 18.1 M |
All numbers in USD currency
Indicator range from annual reports
Maximum | Minimum | Average |
---|---|---|
149 M | 18.1 M | 59.8 M |
Quarterly General and Administrative Expenses Halozyme Therapeutics
2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
41.2 M | 35.7 M | 35.1 M | - | 35.3 M | 38.9 M | 37.4 M | - | 34.5 M | 57.5 M | 13.8 M | - | 13.2 M | 12.3 M | 11.1 M | - | 11.7 M | 11 M | 12.6 M | - | 18 M | 17.3 M | 18 M | - | 14.9 M | 14.4 M | 13.6 M | - | 13.3 M | 13.1 M | 12.6 M | - | 11.6 M | 11.2 M | 10.8 M | - | 10.2 M | 9.81 M | 9.4 M | - | 8.59 M | 8.75 M | 10.2 M | - | 8.14 M | 7.3 M | 7.56 M | - | 5.63 M | 5.58 M | 6.62 M | - | 4.26 M | 4.57 M | 3.41 M |
All numbers in USD currency
Indicator range from quarterly reporting
Maximum | Minimum | Average |
---|---|---|
57.5 M | 3.41 M | 16.2 M |